George Scangos

Last updated

George A. Scangos
NationalityAmerican
Alma mater Cornell University, University of Massachusetts
Scientific career
Fields Biotechnology
Institutions Johns Hopkins University, Biogen
Doctoral advisor Albey Reiner
Other academic advisors Frank Ruddle

George A. Scangos was a pharmaceutical executive and former chief executive officer of Vir Biotechnology from 2017 to 2023. Scangos was previously the chief executive officer of Biogen from 2010 to 2016 and of Exelixis from 1996 to 2010. [1] [2] Prior to joining industry, Scangos was a professor of biology at Johns Hopkins University. [3] [4]

Contents

Education

He has a BA in biology from Cornell University in 1991. He worked briefly as a lab technician at MIT and then became a sales rep for a lab supply company. Trying to get into a graduate school, he drove out to University of Massachusetts and despite never taking a microbiology course, ended up with a PhD in microbiology from the University of Massachusetts with Albey Reiner in 1977. [5] He then did his postdoctoral fellowship with Frank Ruddle at Yale University where they created the first transgenic mouse. [6]

Career

He was a professor of biology at Johns Hopkins University for six years before taking a sabbatical to join Molecular Diagnostics which was co-founded by Ruddle. Molecular Diagnostics and Molecular Therapeutics were acquired by Bayer and he was recruited to Bayer Biotechnology to expand their labs in 1989. With Bayer, he would lead the development of Factor VIII (medication) at the Berkeley, California campus [3] [7] [4]

In 1996, Scangos joined Exelixis and took the company public and was responsible for building its cancer pipeline and setting up multiple partnerships. Exelixix would move to California and move into small molecule discovery and development. [4] He was named CEO of Biogen Idec during the strategic battle with Carl Icahn and made a number of major changes in the direction of the company including closing down the San Diego site, moving headquarters back to Cambridge and dropping the old Idec name. This also including the pivot from oncology research to risky pipeline projects in neurology and hematology including the development of drugs for multiple sclerosis and Alzheimer's like aducanumab. [8] [7] [9] [10] Scangos was named CEO during the launch of Vir. He would serve as the chair of PhRMA in 2016 and was the lead of the Biotechnology Innovation Organization's response to COVID-19. [11] [12] [13]

Personal life

Scangos grew up in Lynn, Massachusetts and is of Greek descent. His father was an accountant at Exxon. His grandparents came to the US from Greece. [12]

Related Research Articles

<span class="mw-page-title-main">Walter Gilbert</span>

Walter Gilbert is an American biochemist, physicist, molecular biology pioneer, and Nobel laureate.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

<span class="mw-page-title-main">Phillip Allen Sharp</span> American geneticist and molecular biologist

Phillip Allen Sharp is an American geneticist and molecular biologist who co-discovered RNA splicing. He shared the 1993 Nobel Prize in Physiology or Medicine with Richard J. Roberts for "the discovery that genes in eukaryotes are not contiguous strings but contain introns, and that the splicing of messenger RNA to delete those introns can occur in different ways, yielding different proteins from the same DNA sequence". He has been selected to receive the 2015 Othmer Gold Medal.

<span class="mw-page-title-main">Exelixis</span> American biotechnology company

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.

James L. "Jim" Vincent was the chairman and CEO of Biogen Idec from 1985 to 2002. He graduated from Duke University's Pratt School of Engineering in 1961 with a Bachelor of Science degree, and received an MBA from the Wharton School of Business at the University of Pennsylvania in 1963. He was a member of the board of directors of Alnylam Pharmaceuticals and served as a trustee of Duke University for 12 years. He had two children, Aimee (Vincent) Jamison and Christopher Vincent.

Howard Civian Birndorf is a biotechnology entrepreneur and one of the founders of the biotech industry in San Diego, California.

<span class="mw-page-title-main">Ivor Royston</span> Researcher

Ivor Royston, M.D., is an oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines. He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.

Christoph Westphal is an American biomedical businessman.

Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.

<span class="mw-page-title-main">Vicki Sato</span>

Vicki L. Sato is a retired professor of management practice at Harvard Business School and a professor of the practice in the department of molecular and cell biology at Harvard University. Since 2021, she has been a member of the President’s Council of Advisors on Science and Technology (PCAST).

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Michael Bonney</span> American businessman and former pharmaceutical executive

Michael "Mike" Weston Bonney is an American businessman and former pharmaceutical executive. Bonney was the president and chief executive officer of Cubist Pharmaceuticals, from 2003 until his retirement in 2014 coinciding with the company being acquired by Merck & Co. for $9.5 billion.

PDL BioPharma is a publicly traded American holding company that since 2008 manages patents and other intellectual property that had been generated by the company. In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it capitalized with $400 million.

Arrakis Therapeutics is a Waltham, Massachusetts-based biopharmaceutical company developing drugs for neurological disorders and other diseases. The company was co-founded in 2015 by Jennifer Petter, PhD, now Chief Innovation Officer Raj Parakh, Alan Walts and Henri Termeer. Arrakis has been led since October 2016 by CEO Michael Gilman, PhD, a former Biogen executive who co-founded and led Padlock Therapeutics and Stromedix.

<span class="mw-page-title-main">Gregory L. Verdine</span> American chemical biologist

Gregory L. Verdine is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.

James C. “Jim” Mullen was the president and CEO of Biogen Idec until he retired effective June 8, 2010. At the same time, he started he would retire from the board at the end of his term. In 2011, he was named CEO to drug manufacturer Patheon, based in Durham, North Carolina, as well as to their board. He stayed there until August 29, 2017.

<span class="mw-page-title-main">William Rastetter</span> American scientist, entrepreneur and venture capitalist

William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Entos, Inc.. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.

John Maraganore is an American scientist, entrepreneur, and life sciences industry leader.

References

  1. ↑ Fidler, Ben (January 25, 2023). "Veteran biotech leader George Scangos to step down as Vir CEO". BioPharma Dive. Retrieved April 5, 2023.
  2. ↑ "George Scangos". www.bizjournals.com.
  3. 1 2 "Biogen Idec Names George Scangos Chief Executive Officer" . Retrieved April 5, 2023.
  4. 1 2 3 Ribbink, Kim (March 25, 2009). "Dr. George Scangos: Gene Excellence". PharmaVoice. Retrieved April 6, 2023.
  5. ↑ Scangos, Georg A.; Reiner, Albey Mahesh (March 1, 1979). "A unique pattern of toxic synthesis in pentitol catabolism: Implications for evolution". Journal of Molecular Evolution. 12 (3): 189–195. doi:10.1007/BF01732338.
  6. ↑ Gordon, J W; Scangos, G A; Plotkin, D J; Barbosa, J A; Ruddle, F H (December 1980). "Genetic transformation of mouse embryos by microinjection of purified DNA". Proceedings of the National Academy of Sciences. 77 (12): 7380–7384. doi:10.1073/pnas.77.12.7380.
  7. 1 2 Timmerman, Luke (August 31, 2011). "George Scangos, the Boy From Working Class Boston, on His Road Back to Lead Biogen Idec". Xconomy Boston. Retrieved April 6, 2023.
  8. ↑ Fidler, Ben (July 21, 2016). "With Biogen at a Crossroads, CEO Scangos to Step Down | Xconomy". Xconomy Boston. Retrieved April 6, 2023.
  9. ↑ Mitchell, Peter (January 1, 2011). "Biogen Idec restructures, sharpens neurology focus". Nature Biotechnology. 29 (1): 7–8. doi:10.1038/nbt0111-7. PMID   21221080.
  10. ↑ Timmerman, Luke (June 16, 2011). "Biogen Idec CEO on Move Back to Cambridge: "We're Working on It"". Xconomy Boston. Retrieved April 6, 2023.
  11. ↑ "Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor". BioSpace. January 25, 2023.
  12. 1 2 Kampouris, Nick (March 9, 2020). "Greek-American Scientist Heads Global Campaign for Coronavirus Treatment". Greek Reporter. Retrieved April 5, 2023.
  13. ↑ Mast, Jason (January 25, 2023). "Vir CEO George Scangos to retire, after pandemic success". STAT.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.